Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving < sup > 177 < /sup > Lu-DOTATATE therapy?

CONCLUSION: The pre-treatment SUVmax values of 68Ga-DOTATATE PET/CT in lesions are a potential prognostic factor for PFS in well-differentiated gastroenteropancreatic neuroendocrine tumors undergoing 177Lu-DOTATATE treatment, and could be a useful parameter for the treatment selection.PMID:34352047 | DOI:10.1967/s002449912352
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Source Type: research